Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
Top Cited Papers
- 1 June 2002
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 359 (9323), 2053-2058
- https://doi.org/10.1016/s0140-6736(02)08937-7
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2Circulation, 2002
- Medical Treatment of Peripheral Arterial Disease and ClaudicationNew England Journal of Medicine, 2001
- Effect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial PerfusionCirculation, 2000
- Meeting HighlightsCirculation, 1999
- Gene Therapy for Myocardial AngiogenesisCirculation, 1998
- Cilostazol Has Beneficial Effects in Treatment of Intermittent ClaudicationCirculation, 1998
- Induction of Neoangiogenesis in Ischemic Myocardium by Human Growth FactorsCirculation, 1998
- Clinical Applications of Research on AngiogenesisNew England Journal of Medicine, 1995
- A Comparison of Angioplasty with Medical Therapy in the Treatment of Single-Vessel Coronary Artery DiseaseNew England Journal of Medicine, 1992
- Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patientsAmerican Heart Journal, 1982